Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug379 | BLD-2660 Wiki | 0.35 |
drug4023 | prophylactic lactoferrin daily Wiki | 0.35 |
drug2324 | Online support Group Wiki | 0.35 |
Name (Synonyms) | Correlation | |
---|---|---|
drug3370 | Testing of SARS-CoV-2 antibodies Wiki | 0.35 |
drug376 | BIO101 Wiki | 0.35 |
drug2556 | Placebo oral capsule; From August 2020 'no additional treatment' Wiki | 0.35 |
drug2979 | SPIN-CHAT Program Wiki | 0.35 |
drug2626 | Prednisolone 5 mg Wiki | 0.35 |
drug697 | Cannabis, Medical Wiki | 0.35 |
drug2490 | Placebo Wiki | 0.02 |
Name (Synonyms) | Correlation | |
---|---|---|
D009103 | Multiple Sclerosis NIH | 0.62 |
D012595 | Scleroderma, Systemic NIH | 0.50 |
D000690 | Amyotrophic Lateral Sclerosis NIH | 0.50 |
Name (Synonyms) | Correlation | |
---|---|---|
D016472 | Motor Neuron Disease NIH | 0.50 |
D012594 | Scleroderma, Localized NIH | 0.35 |
D000070627 | Chronic Traumatic Encephalopathy NIH | 0.35 |
D005879 | Tourette Syndrome NIH | 0.35 |
D003424 | Crohn Disease NIH | 0.35 |
D000070642 | Brain Injuries, Traumatic NIH | 0.25 |
D012640 | Seizures NIH | 0.25 |
D006526 | Hepatitis C NIH | 0.25 |
D001714 | Bipolar Disorder NIH | 0.20 |
D005356 | Fibromyalgia NIH | 0.18 |
D000755 | Anemia, Sickle Cell NIH | 0.18 |
D001930 | Brain Injuries, NIH | 0.16 |
D001927 | Brain Diseases NIH | 0.16 |
D005221 | Fatigue NIH | 0.16 |
D010300 | Parkinsonian NIH | 0.14 |
D015212 | Inflammatory Bowel Diseases NIH | 0.13 |
D059350 | Chronic Pain NIH | 0.12 |
D040921 | Stress Disorders, Traumatic NIH | 0.07 |
D004194 | Disease NIH | 0.07 |
D013313 | Stress Disorders, Post-Traumatic NIH | 0.07 |
D014947 | Wounds and Injuries NIH | 0.06 |
D013577 | Syndrome NIH | 0.03 |
D003141 | Communicable Diseases NIH | 0.03 |
D007239 | Infection NIH | 0.02 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.01 |
D018352 | Coronavirus Infections NIH | 0.01 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0006802 | Abnormal anterior horn cell morphology HPO | 0.50 |
HP:0007354 | Amyotrophic lateral sclerosis HPO | 0.50 |
HP:0012344 | Morphea HPO | 0.35 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0100280 | Crohn's disease HPO | 0.35 |
HP:0100754 | Mania HPO | 0.25 |
HP:0001250 | Seizure HPO | 0.20 |
HP:0012378 | Fatigue HPO | 0.16 |
HP:0001298 | Encephalopathy HPO | 0.16 |
HP:0002037 | Inflammation of the large intestine HPO | 0.13 |
HP:0012532 | Chronic pain HPO | 0.12 |
Navigate: Correlations HPO
There are 8 clinical trials
This is a randomised placebo-controlled study of moderate dose prednisolone for 6 months in patients with early diffuse cutaneous systemic sclerosis (dcSSc). Seventy-two patients within 3 years of the onset of skin thickening will be recruited from 14 UK centres over 3 years. Co-primary end-points will be the Health Assessment Questionnaire Disability Index (HAQ-DI) and the modified Rodnan skin score (mRSS). Patients will be assessed 5 times: screening, baseline, 6 weeks, 3 and 6 months, with a code-break on exit from the study at 6 months. Please note: From August 2020, the trial was re-started following halt due to Covid-19 as open-label. The placebo arm is the 'no treatment' arm and there is no longer a code-break at study exit.
Description: The mean difference in HAQ-DI at 3 months
Measure: Health Assessment Questionnaire Disability Index (HAQ-DI) Time: Baseline to 3 monthsDescription: The difference in mRSS at 3 months
Measure: modified Rodnan Skin Score (mRSS) Time: Baseline to 3 monthsDescription: HAQ-DI
Measure: Quality of life and functional ability - Assessed by Questionnaire Time: Baseline to 6 weeks and 6 monthsDescription: Skin involvement as measured by the mRSS
Measure: Pain and disability Time: Baseline to 6 weeks and 6 monthsDescription: 11-point Scleroderma Functional Index
Measure: Functional ability - Assessed by Questionnaire Time: Baseline to 6 weeks, 3 months and 6 monthsDescription: Assessment of Pruritus
Measure: Pain associated with itch - Assessed by Questionnaire Time: Baseline to 6 weeks, 3 months and 6 monthsDescription: Cochin Hand Function
Measure: Hand function - Assessed by Questionnaire Time: Baseline to 6 weeks, 3 months and 6 monthsDescription: Functional Assessment of Chronic Illness Therapy (FACIT)
Measure: Fatigue - Assessed by Questionnaire Time: Baseline to 6 weeks, 3 months and 6 monthsDescription: Hospital Anxiety and Depression Scale (HADS) . This questionnaire has 14 questions, each with 4 options designed to assess aspects of mental health
Measure: Anxiety and depression - Assessed by questionnaire Time: Baseline to 6 weeks, 3 months and 6 monthsDescription: Helplessness Questionnaire
Measure: Health related quality of life - Assessed by Questionnaire Time: Baseline to 6 weeks, 3 months and 6 monthsDescription: Short Form (36) Health Survey
Measure: Health related quality of life - Assessed by Questionnaire Time: Baseline to 6 weeks, 3 months and 6 monthsDescription: EuroQol 5 Dimensions
Measure: Health related quality of Life - Assessed by Questionnaire Time: Baseline to 6 weeks, 3 months and 6 monthsDescription: Patient Global Assessment
Measure: Pain and disability Time: Baseline to 6 weeks, 3 months and 6 monthsDescription: Physician Global Assessment
Measure: Pain and disability Time: Baseline to 6 weeks, 3 months and 6 monthsDescription: Digital Ulcer Count: The site and total number of ulcers on the hand are recorded by the patients clinician on a diagram of a hand
Measure: Assessment of pain - Clinician assessment Time: Baseline to 6 weeks, 3 months and 6 monthsDescription: Tender Friction Rubs - the total number of tendon friction rubs on 12 possible anatomical sites are recorded
Measure: Assessment of pain - Clinician assessment Time: Baseline to 6 weeks, 3 months and 6 monthsDescription: Joint Count: The number of tender or swollen joints are assessed from 14 anatomical sites (both left and right side) and recorded out of a total of 28 (14 sites, left and right side) tender joints and 28 swollen joints
Measure: Assessment of pain - Clinician assessment Time: Baseline to 6 weeks, 3 months and 6 monthsDescription: Assessment of Arthritis Index
Measure: Pain and disability - Assessed by Questionnaire Time: Baseline to 6 weeks, 3 months and 6 monthsDescription: Assessment in percentage change of mRSS
Measure: Pain and disability Time: Baseline to 6 weeks, 3 months and 6 monthsThis will be a multistate, multicenter clinical study to determine the efficacy and safety of medical cannabis for a wide variety of chronic medical conditions.
Description: Covid-19 infection rates in cannabis users will be compared to rates in the general population. Our online questionnaire responses will compare infection rates of cannabis users in this study against the Johns Hopkins University Coronavirus Research Center data (https://coronavirus.jhu.edu).
Measure: Prevention of COVID-19 Time: Five yearsDescription: Severity of persistent symptoms in cannabis users testing positive for active infection and/or antibodies will also be compared to the general population. Patients will answer the widely used FLU-PRO questionnaire, which asks about flu symptoms and severity, to capture diagnoses, symptoms, and medical interventions related to COVID-19. The data from cannabis user patients will be compared with national and international data surveys, such as the Covid Symptom Study (https://covid.joinzoe.com/us-2).
Measure: Treatment of COVID-19 Time: Five yearsDescription: The primary objective is to assess the efficacy and safety of medical cannabis as medicine for treatment of chronic pain and other chronic debilitating diseases. Pain will be measured by Brief Pain Inventory (BPI) numeric scale. Change from baseline in BPI will be assessed at 3-month intervals. For prospective associations between cannabis use and outcomes, use of a lagged mixed-effects models will examine temporal associations between cannabis use and pain severity, opioid sparing, and patient satisfaction. Data will be analyzed from baseline and the annual follow-up waves.
Measure: Treatment of Symptoms Time: Five yearsDescription: Secondary objectives include evaluating increases or decreases in quality of life, and increases or decreases in concomitant opioid use. Satisfaction with treatment will be measured by a Visual Analog Score (VAS). Change From baseline in Satisfaction with treatment measured by (VAS) be assessed at 3-month intervals.
Measure: Cannabis Impact on Quality of Life Time: Five yearsDescription: Tertiary objectives will examine preferences for routes of administration, and preferences for THC / CBD ratios. Categorical factors will be summarized using frequencies and percentages, while continuous measure distributions will be described using means, standard deviations, and quartiles of interest.
Measure: Cannabis Route and Dosing Time: Five yearsDescription: Incidence of Treatment-Related Adverse Events will be measured by Physician Global Assessment (PGA) numeric scale. Number of participants with Treatment-Related Adverse Events will be assessed by CTCAE v4.0.
Measure: Monitoring Adverse Events Time: Five yearsContagious disease outbreaks, such as the coronavirus disease 2019 (COVID-19) outbreak, and associated restrictions to prevent spread can lead to negative psychological outcomes, including loneliness, depression, and anxiety, particularly in vulnerable populations at risk due to existing medical conditions. To date, no randomized controlled trials have tested interventions to reduce mental health consequences of contagious disease outbreaks. Systemic sclerosis (SSc; scleroderma) is a rare, chronic, autoimmune disease characterized by vasculopathy and excessive collagen production. Systemic Sclerosis can affect multiple organ systems, including the skin, lungs, gastrointestinal tract, and heart. Many people with scleroderma are at risk of serious complications from COVID-19 if infected due to lung involvement (> 40% have interstitial lung disease) and common use of immunosuppressant drugs. The objective of The Scleroderma Patient-centered Intervention Network COVID-19 Home-isolation Activities Together (SPIN-CHAT) Trial is to evaluate a videoconference-based intervention designed to improve symptoms of anxiety and other mental health outcomes among individuals with systemic sclerosis at risk of poor mental health during the COVID-19 pandemic. The trial is a pragmatic randomized controlled trial that will be conducted using an existing cohort of systemic sclerosis patients. We will use a partially nested design to reflect dependence between individuals in training groups but not in the waitlist control. The SPIN-CHAT Program includes activity engagement, education on strategies to support mental health, and mutual participant support.
Description: The PROMIS Anxiety 4a v1.0 is a 4 item scale that asks participants, in the past 7 days, how often: (1) "I felt fearful"; (2) "I found it hard to focus on anything other than my anxiety"; (3) "My worries overwhelmed me"; and (4) "I felt uneasy". Items are scored on a 5-point scale (range 1-5), and response options include "never", "rarely", "sometimes", "often", and "always". Higher scores represent more anxiety. PROMIS Anxiety 4a v1.0 has been validated in SSc.
Measure: Anxiety: Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety 4a v1.0 Time: 4-weeks post-randomizationDescription: The PROMIS Anxiety 4a v1.0 is a 4 item scale that asks participants, in the past 7 days, how often: (1) "I felt fearful"; (2) "I found it hard to focus on anything other than my anxiety"; (3) "My worries overwhelmed me"; and (4) "I felt uneasy". Items are scored on a 5-point scale (range 1-5), and response options include "never", "rarely", "sometimes", "often", and "always". Higher scores represent more anxiety. PROMIS Anxiety 4a v1.0 has been validated in SSc.
Measure: Anxiety: Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety 4a v1.0 Time: 10-weeks post-randomizationDescription: PHQ-8 items measure depressive symptoms over the last 2 weeks on a 4-point scale, ranging from 0 (not at all) to 3 (nearly every day) with higher scores (range 0 to 24) indicating more depressive symptoms. The PHQ-8 performs equivalently to the PHQ-9, which has been shown to be a valid measure of depressive symptoms in patients with scleroderma.
Measure: Depression symptoms: Patient Health Questionnaire (PHQ-8) Time: 4-weeks post-randomization, 10-weeks post-randomizationDescription: The 6-item ULS-6 is a short version of the 20-item ULS, which is designed to assess subjective feelings of loneliness and social isolation. Respondents indicate the degree to which feelings described in each item apply to them. Items are scored on a 4-point scale from 0 (never) to 3 (often); total scores range from 0 to 18.
Measure: Loneliness: University of California, Los Angeles (UCLA) Loneliness Scale (ULS-6) Time: 4-weeks post-randomization, 10-weeks post-randomizationDescription: The full MSBS is a 29-item measure of state boredom with items on five factors that load onto a single higher-order factor. The 8-item MSBS is a short version with scores that correlate very closely to scores from the full MSBS (r = 0.96) Item responses are on a 7-point Likert-type scale from 1 (strongly disagree) to 7 (strongly agree) and assess the degree to which each item reflects the respondant's experience currently. Total scores range from 8 to 56 with higher scores reflecting greater boredom.
Measure: Boredom: Multidimensional State Boredom Scale (MSBS-8) Time: 4-weeks post-randomization, 10-weeks post-randomizationDescription: The 4-item IPAQ-E is a short-form version of the full IPAQ designed to assess physical activity over the last week, including time spent sitting, walking, and in moderate and vigorous physical activity. Compared to other short-form versions of the IPAQ, the IPAQ-E has examples of exercise specific to older adults.
Measure: Physical activity: International Physical Activity Questionnaire - modified for the elderly (IPAQ-E) Time: 4-weeks post-randomization, 10-weeks post-randomizationDescription: Adverse Effects will be assessed by ongoing monitoring during the trial and by asking participants post-intervention to describe any adverse experiences or outcomes that may have occurred.
Measure: Adverse Effects Time: 4-weeks post-randomization, 10-weeks post-randomizationDescription: The COVID-19 Fears Questionnaire for Chronic Medical Conditions is a 10-item scale that ask participants to rate, on a typical day in the last week, how much they were afraid from "not at all" to "extremely" about aspects of COVID-19. Items are scored on a 5-point scale (range 1-5). Higher scores represent greater fear. The scale has been validated among people with scleroderma.
Measure: Fear: COVID-19 Fears Questionnaire for Chronic Medical Conditions Time: 4-weeks post-randomization, 10-weeks post-randomizationThe aim of the study is to understand the impact of COVID-19 on People with Multiple Sclerosis in the United Kingdom.
Description: Targeted questionnaire dependent on COVID Status
Measure: Incidence of COVID-19 Infections within an MS Cohort in the UK Time: Through study completion, an average of 1 yearDescription: Monitor admission rates in linked population
Measure: Hospitalisations in MS Patients with COVID-19 Time: 1 Year (regular outputs)Description: Death data from routinely reported government level data (HES/PEDW)
Measure: Mortality Time: 1 Year from study commencementDescription: Patient Reported Outcome for MS disability
Measure: Patient Reported Expanded Disability Status Score Time: 1 year (at least 6 monthly)Description: Patient Reported Outcome for anxiety and depression
Measure: Hospital Anxiety and Depression Scale Time: 1 year (at least 6 monthly)Description: Patient Reported Outcome for Multiple sclerosis impact on physical and psychological status
Measure: Multiple Sclerosis Impact Scale 29 V2 Time: 1 year (at least 6 monthly)Description: Patient Reported Outcome for walking status
Measure: Multiple Sclerosis Walking Scale 12 V2 Time: 1 year (at least 6 monthly)Description: Patient Reported Outcome for impact of fatigue
Measure: Fatigue Severity Scale Time: 1 year (at least 6 monthly)Description: Patient Reported Outcome for general quality of life
Measure: EuroQol 5D (3l) Time: 1 year (at least 6 monthly)Stress and anxiety can have an adverse impact on health, and the experience of many around the 2020 outbreak of COVID-19 is affecting health and well-being. Individuals with chronic disease such as multiple sclerosis may be particularly vulnerable in some ways, but also particularly resilient in others. This study evaluates the effects of belonging to online support groups that meet weekly for 12 weeks to address the stress and anxiety felt by individuals with Multiple Sclerosis (MS). This study will also measure and explore the effects of online support groups.
Description: Acceptable rate is defined as at least 66% of participants who complete follow-up surveys.
Measure: Rate of completion Time: Up to 12 weeksDescription: Acceptable rate is defined as at least 66% of sessions being attended.
Measure: Rate of adherence Time: Up to 12 weeksDescription: The STAI is a commonly used measure of trait and state anxiety that is scored from 20 (minimum score) to 80 (maximum score), with a higher scores indicating higher anxiety (worse outcome).
Measure: Score on the State Trait Anxiety Inventory (STAI) Time: Up to 12 weeksDescription: Mood as measured by change in depression or depressive symptoms will be measured with the 8-item PHQ-8 which is scored from 0 (minimum score) to 24 (maximum score), in which higher scores indicate higher depression or depressive symptoms (worse outcome).
Measure: Score on the Personal Health Questionnaire Depression Scale (PHQ-8) Time: Up to 12 weeksHundreds of thousands of confirmed cases have been reported worldwide, just 3 months after the first patients were identified in Wuhan, China. Just like other members of the community, MS patients are uncomfortable with the emotional distress and health anxiety caused by the COVID-19 outbreak. Most MS patients receive immunosuppressive or immunomodulatory therapies. Patients taking immunosuppressive agents are theoretically at increased risk of being affected by viral pandemics, and a higher health concern is expected in this group of patients. Moreover, MS patients lose social support. Patients with increased duration of stay can no longer access physical and cognitive rehabilitation therapies. We also know that increased anxiety and sleep disorders can cause MS patients to have an attack. When literature is examined, it is known that MS patients' physical activity levels decrease, fatigue, sleep quality and anxiety levels increase, so their quality of life and participation in daily life activities decrease. MS patients lose social support during the COVID-19 outbreak. For all these reasons, we think that the fatigue, physical activity level, anxiety level and sleep disturbances affected before the COVID-19 outbreak will be further affected for these reasons.
Description: Fatigue was assessed by the Fatigue Severity Scale (FSS). This is a 9-item questionnaire that assesses the effect of fatigue on daily living. Each item is a statement on fatigue that the subject rates from 1 "completely disagree" to 7 "completely agree". A score of 4 or higher generally indicates severe fatigue
Measure: Fatigue Time: 4 weekDescription: Physical activity levels were assessed by the International Physical Activity Questionnaire (IPAQ): short form. The online self-reporting questionnaire consisted of questions investigating the respondents' PA practice in terms of frequencies and durations of sitting, walking, moderate-intensity physical activities and vigorous-intensity physical activities. The MET-minutes per week (MET-min/week) were calculated using the following formula: intensity (MET) x duration x frequency. Physical activity levels were classified as physically inactive (<600 MET-min/week), with low levels of physical activity (600-3000 MET- min/week) and physical activity level that is sufficient (> 3000 MET-min/week)
Measure: Physical activity Time: 4 weekDescription: The Pittsburgh Sleep Quality Index (PSQI) questionnaire was used to measure sleep quality using an 18-item scale containing seven items that included sleep quality, sleep duration, sleep latency, habitual sleep efficiency, sleep disturbance, use of sleeping medications, and daytime dysfunction. Each dimension scored between 0-3, with a total score ranging from 0-21, and a higher score indicating lower sleep quality.
Measure: Sleep quality Time: 4 weekDescription: The Hospital Anxiety and Depression Scale (HADS) was composed by two subscales (i.e., anxiety and depression), with 7-items each. The anxiety part of HADS was used to evaluate the anxiety levels of the patients. Each dimension scored between 0-3, with a total score ranging from 0-21, and a higher score indicating higher anxiety level.
Measure: Anxiety Time: 4 weekRationale: Patients with MS are possibly more vulnerable to infection with SARS-CoV-2. Furthermore the use of immunomodulatory treatment could have an effect on the course of COVID-19 disease. This has resulted in an alteration of current immunomodulatory treatment strategies and delaying the start of certain medications, which could induce MS disease activity. However, certain immunomodulatory treatments are also hypothesized to have a positive effect on COVID-19 disease. Besides lack of information regarding the effects of MS treatments on COVID-19, there is significant uncertainty in how we should advise MS patients in terms of self-isolation, resulting in many patients staying at home reluctant to perform their work or other daily activities. Nationally and locally, we are collecting information regarding COVID-19 in MS patients but numbers are low and only those who are severely affected are tested. Furthermore, there is no information regarding SARS-CoV-2 immunity in MS patients, which could be affected by certain MS treatments. Consequently, there is an urgent need for reliable information about infection rates/immunity and course of COVID-19 in relation to MS characteristics and treatments. Objectives: The objectives of this study are 1. to study the course of COVID-19 in MS patients in relation to immunomodulatory treatment and other patient and MS characteristics and 2. to study the proportion of MS patients with SARS-CoV-2 antibodies and 3. to establish the antibody profile in positive tested patients and 4. to study the longitudinal course of these antibody profiles in positive tested patients. Study design: This is a mono-center cohort study in patients of the MS Center Amsterdam. Study population: All patients with a diagnosis of MS currently under follow-up in the Amsterdam MS Center. Intervention (if applicable): Single venous puncture for drawing blood and questionnaire. For a minority of patients (max 25%) who test positive for antibodies we will draw blood a again with questionnaires after six and twelve months. Main study parameters/endpoints: Course of COVID-19 in MS patients in relation to MS immunomodulatory treatment.
Description: Correlationg of disease course of COVID-19 in patients with positive SARS-CoV-2 antibodies defined by questionnaires (asymptomatic, mild symptoms, severe symptoms, hospitalization) with MS immunomodulatory treatment (asked by questionnaires)
Measure: The correlation of COVID-19 disease course with MS immunomodulatory treatment Time: at baseline questionnaires and lab resultsAmyotrophic lateral sclerosis (ALS) is a relentlessly progressive and fatal neurodegenerative disease characterized by progressive weakness involving limb, bulbar, and respiratory muscles.There is currently no information suggesting how COVID-19 affects patients diagnosed with amyotrophic lateral sclerosis (ALS). This is especially important as respiratory compromise is common in ALS patients and can complicate the clinical course as COVID-19 could lead to respiratory failure and need for intubation. We intend that this registry will guide our understanding of how COVID-19 affects patients with ALS.
Description: Assessed through outcomes reporting ranging from recovered infections to patient death reported in a patient facing registry.
Measure: COVID-19 incidence and prevalence in the ALS population Time: Data will be collected through study completion, an average of 3 yearsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports